Menopause

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Staff January 4, 2024

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and...

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Staff December 26, 2023

$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Staff December 20, 2023

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20,...

Women’s Health Associates Selects AI-powered, Ambient Listening Technology Sunoh.ai to Transform Clinical Documentation and Improve Quality Care

Staff December 7, 2023

The women’s health practice aims to streamline documentation, provide personalized attention to its patients, and drive efficiencies by leveraging the...

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Staff December 4, 2023

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE)...

Biodentical Hormone Therapy Awareness Advanced By Suzanne Somers, Says Dr. Paul Savage

Staff November 20, 2023

Dr. Savage, CEO of MDLifespan in Chicago, says that by sharing her personal story she advanced awareness of Biodentical Hormone...

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Staff November 20, 2023

Partnership Aims to Advance Daré’s Reproductive Health Portfolio in a Timely and Capital Efficient MannerSAN DIEGO and MORRISVILLE, N.C., Nov....

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Staff November 13, 2023

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic...

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Staff November 9, 2023

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of...

Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST

Staff September 22, 2023

Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CEST Liege, Belgium, September 21,...

Information on the total number of voting rights (denominator)

Staff September 22, 2023

Information on the total number of voting rights (denominator) Liege, Belgium, 21 September 2023 – 5:45 pm CEST – Mithra...

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Staff September 21, 2023

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...

Mithra prices private placement to raise EUR 20 million in equity

Staff August 24, 2023

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Staff August 16, 2023

JERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Staff August 10, 2023

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene®...

Science & Humans (S&H) Welcomes Esteemed Canadian Endocrinologist & Geneticist Dr. Fady Hannah-Shmouni to Medical Advisory Board

Staff August 8, 2023

MISSISSAUGA, ON / ACCESSWIRE / August 8, 2023 / Science & Humans (S&H), a health and wellness company focused on...

Progyny Unveils Nationwide Access to Menopause Care

Staff August 4, 2023

Integrative approach with leading providers Gennev and Midi Health to advance equitable and accessible workplace support for individuals experiencing menopause...

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Staff July 31, 2023

Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and...

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Staff July 12, 2023

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Staff July 11, 2023

Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire...